ライフサイエンスコーパス: FTT

1 r accuracy in diagnosing RCT of any sort and FTT.

2 setting, which is most commonly achieved by FTT in academic practices.

3 Retinal blood flow as measured by FTT was reduced with higher levels of CVP.

4 is of breast cancer were injected with (18)F-FTT and imaged dynamically 0-60 min after injection over

5 studies and the initial validation of (18)F-FTT as an imaging-based biomarker for measuring PARP-1 e

6 ot iniparib, significantly reduced the (18)F-FTT AUC in the spine (median difference before and after

7 ot iniparib, significantly reduced the (18)F-FTT AUC in the spine (median difference before and after

8 Tumor (18)F-FTT distribution volume ratios relative to normal muscle

9 was estimated at 6.9 mSv for a 370-MBq (18)F-FTT dose in humans.

10 This study intends to characterize (18)F-FTT pharmacokinetics in breast cancer and optimize image

11 onded to expression of PARP-1 and that (18)F-FTT quantitation is influenced by radiometabolites that

12 Conclusion: This study of PARPi analog (18)F-FTT showed that uptake kinetics in vivo corresponded to

13 secondary aim is to determine whether (18)F-FTT uptake in breast cancer correlates with matched froz

14 Conclusion The results suggest that (18)F-FTT uptake reflects PARP expression and that its radiati

15 ects with measurable tumors, increased (18)F-FTT uptake was seen in one subject with pancreatic adeno

16 ter injection may sufficiently balance (18)F-FTT uptake with background clearance and radiometabolite

17 teristic curve (AUC, in g/mL. min) for (18)F-FTT was assessed in normal mouse organs before and after

18 Rapid metabolism of (18)F-FTT was demonstrated in mice, and similar uptake of radi

19 Results: Pharmacokinetics of (18)F-FTT were well fit by Logan plot reference region models

20 Fluorine 18 ((18)F) fluorthanatrace ((18)F-FTT) is a PET radiotracer for imaging poly (adenosine di

21 (18)F-fluorthanatrace ((18)F-FTT) is an analog to rucaparib, a clinically approved PA

22 istry, Radiotracer Development, PARPi, (18)F-FTT, Investigational New Drug (C) RSNA, 2022.

23 erify the human radiation dosimetry of (18)F-FTT.

24 thelial ovarian cancer underwent both [(18)F]FTT and [(18)F]FDG PET before new oncologic treatment.

25 The SUV(max) of [(18)F]FTT and [(18)F]FDG was compared between lesions.

26 Conclusion: Our findings suggest that [(18)F]FTT PET may provide unique information on ovarian cancer

27 No correlation was found between [(18)F]FTT SUV(max) and [(18)F]FDG SUV(max) per lesion, support

28 [(18)F]FTT SUV(max) was compared with tumor location, tumor gra

29 [(18)F]FTT uptake varied widely across lesions, with no signifi

30 n this study, [(18)F]fluorthanatrace ([(18)F]FTT), a PET radiotracer for imaging PARP1, was compared

31 T) with fluorine 18 ((18)F) fluorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribos

32 Defects were reconstructed as follows: FTT (161 patients [52.1%]), RC (64 [20.7%]), and PC (84

33 mafic rocks could be an important factor for FTT synthesis during water-rock interaction in mid-ocean

34 eawater bicarbonate as the carbon source for FTT reactions, suggesting that a mantle-derived inorgani

35 dren with elevated sweat chloride, infantile FTT, and recurrent hyponatremia were homozygous for a no

36 chloride, recurrent hyponatremia, infantile FTT and lung disease identified deleterious variants in

37 preventing hypothermia during microsurgical FTT to the head and neck may decrease the postoperative

38 underscoring the functional specification of FTT-2 and PAR-5 despite their high sequence homology.

39 n of rotator cuff tears of any type (RCT) or FTT.

40 We identified the 14-3-3 protein FTT-2 to be a new regulatory component of this pathway.

41 espect to full thickness rotator cuff tears (FTT).

42 Our results indicate that FTT-2 binds to DAF-16 in C. elegans and regulates DAF-16

43 ing co-immunoprecipitation, we revealed that FTT-2 formed a complex with GFP-fused DAF-16 in C. elega

44 A PCF was noted in 36 of 161 patients in the FTT group (22.4%), 25 of 64 in the RC group (39.1%), and

45 ed sweat chloride levels, failure to thrive (FTT), and lung disease are characteristic features of cy

46 ea of CNP, retinal fluorescein transit time (FTT), and an evaluation for rubeosis iridis were perform

47 on after microsurgical free tissue transfer (FTT) to the head and neck.

48 ional closure (RC), or free tissue transfer (FTT).

49 biogenic production by Fischer-Tropsch type (FTT) reactions, although clear evidence for such a proce

50 Fischer-Tropsch type (FTT) synthesis has long been proposed to account for the

51 Undergoing FTT was associated with a clinically meaningful reductio

52 r risk of PCF compared with those undergoing FTT (PC: RR, 2.2 [95% CI, 1.1-4.4]; RC: RR, 2.5 [95% CI,

53 PCF (RR, 1.2; 95% CI, 0.5-2.8) compared with FTT with cutaneous inset.

54 of C1 to C4 hydrocarbons is compatible with FTT genesis.

55 underwent head and neck reconstruction with FTT between January 1, 2012, and August 31, 2023.